Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Genesis Healthcare (GEN) Stock Forecast & Price Target

Genesis Healthcare logo
Get the Latest News and Ratings for GEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genesis Healthcare and its competitors.

Sign Up

GEN Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$29.33$27.20$27.20$23.67
Forecasted Upside0.77% Upside0.04% Upside8.11% Upside42.31% Upside
Consensus Rating
Moderate Buy
Hold
Hold
Buy

GEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genesis Healthcare Stock vs. The Competition

TypeGenesis HealthcareBusiness Services CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside6.53% Upside322.17% Upside10.08% Upside
News Sentiment Rating
Neutral News

See Recent GEN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$35.00 ➝ $37.00+27.10%
10/31/2024Barclays
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00+11.48%
8/2/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetSector Perform ➝ Sector Perform$25.00 ➝ $28.00+11.29%
6/7/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$28.00 ➝ $27.00+6.13%
5/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$26.00 ➝ $29.00+16.51%
11/16/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+26.52%
5/19/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$27.00+67.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:38 PM ET.


GEN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Genesis Healthcare is $29.33, with a high forecast of $37.00 and a low forecast of $25.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GEN shares.

According to analysts, Genesis Healthcare's stock has a predicted upside of 0.77% based on their 12-month stock forecasts.

Genesis Healthcare has been rated by research analysts at Barclays, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.

Analysts like Genesis Healthcare less than other "business services" companies. The consensus rating score for Genesis Healthcare is 2.50 while the average consensus rating score for "business services" companies is 2.68. Learn more on how GEN compares to other companies.


This page (NYSE:GEN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners